Article and Video CATEGORIES

Cancer Journey

Search By

ABOUT
Denise Brock

Denise has over 30 years of varying experience in the healthcare arena.  In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees.  She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.  

 

Targeted Therapies Patient Forum September 2017 update
Author
Denise Brock

GRACE is excited to continue to build the faculty and agenda for the upcoming Targeted Therapies Patient Forum in September 2017.  See below for our growing list of topics and presenters! 

Targeted Therapies in Lung Cancer Patient Forum
September 16, 2017

Presented by the Global Resource for Advancing Cancer Education in collaboration
with the Cleveland Clinic Cancer Center

Register at cancerGRACE.org | Agenda is subject to change

8:30 – 10:00 am        The Many Faces of Progression
Dr. Nathan Pennell Cleveland Clinic Cancer Center The Role of Local Therapy
Dr. Shirish Gadgeel Karmanos Cancer Center, Wayne State University Biopsies & Re-biopsies
Dr. Karen Reckamp, City of Hope
10:30 – noon       
The Question of Clinical Trials
Dr. Alice Shaw Massachusetts General Hospital The Crossroads: Local Therapy, Chemo, Targeted Therapy, or Immunotherapy? 
Panel Discussion with Drs. Pennell, Gadgeel, Reckamp, and Shaw, and patients Matt Hiznay (ALK) and Sara Whitlock (RET). Moderator: Dr. H. (Jack) West

BREAKOUT SESSIONS

1:00 – 2:30 pm     
 
Presentations by Lung Cancer Sub-type
*Available treatment options 
*Acquired resistance: How do you pick your next treatment? 
ALK/ROS Dr. Alice Shaw, Dr. Shirish Gadgeel, & Matt Hiznay, ALK patient
EGFR Dr. Nathan Pennell, Dr. H. (Jack) West, & John Cherol, EGFR patient
MET/RET/BRAF Dr. Karen Reckamp, Dr. Vamsidhar Velcheti (Cleveland Clinic Cancer Center), & Sara Whitlock, RET patient

BREAKOUT SESSIONS

2:50 – 4:00 pm     
 
Managing the Costs of Cancer Care
James P. Stevenson, MD Cleveland Clinic Cancer Center
Patient to Patient Mentoring
Kathryn Sefcek, MHA 4th Angel Mentoring Program
Avoiding Fake News & Finding Trustworthy Cancer Info Online
Dr. H. (Jack) West Swedish Cancer Institute & Founder of cancerGRACE
Janet Freeman-Daily ROS1 patient, #LCSM Twitter Chat co-moderator, Cure Today contributor, Gray Connections blogger

 


 

Introducing Our Speakers

for full faculty bio's, please visit our FACULTY page

***Speaker Highlights***

Learn about ALK patient Matt Hiznay in this video; Matt serves on the event's planning committee and will present during the ALK break-out session.

 

 

Next Previous link

Previous PostNext Post

Related Content

Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
That's beautiful Linda…
By JanineT GRACE … on
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on